Li Z, Zhang XJ, Sun CY, Fei H, Li ZF, Zhao DB. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment. World J Clin Cases 2023; 11(4): 738-755 [PMID: 36818626 DOI: 10.12998/wjcc.v11.i4.738]
Corresponding Author of This Article
Dong-Bing Zhao, MD, Professor, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Pan-Jia-Yuan South Lane, Chaoyang District, Beijing 100021, China. dbzhao@cicams.ac.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zheng Li, Xiao-Jie Zhang, Chong-Yuan Sun, He Fei, Ze-Feng Li, Dong-Bing Zhao, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Li Z and Zhang XJ contributed to the conceptualization; Li Z contributed to the methodology; Sun CY contributed to the software; Li Z and Zhang XJ contributed to the validation; Li Z and Fei H contributed to the formal analysis; Li ZF contributed to the investigation; Zhao DB contributed to the resources; Li Z and Sun CY contributed to the writing-original draft preparation; All authors contributed to the writing-review and editing; Zhao DB contributed to the project administration. All authors have reviewed and agreed to the published version of the manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong-Bing Zhao, MD, Professor, Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Pan-Jia-Yuan South Lane, Chaoyang District, Beijing 100021, China. dbzhao@cicams.ac.cn
Received: October 12, 2022 Peer-review started: October 12, 2022 First decision: December 13, 2022 Revised: December 13, 2022 Accepted: January 3, 2023 Article in press: January 3, 2023 Published online: February 6, 2023
ARTICLE HIGHLIGHTS
Research background
Gastric cancer (GC) is a common malignancy with poor 5-year survival rate. Tumor microenvironment (TME) containing intricate interaction between immune and non-immune cells produces significant impact of the survival of GC. Additionally, CD93 was proved to be associated with abnormal angiogenesis, which could be involved in TME of GC.
Research motivation
This study was conducted to determine the specific role of CD93 in GC in order to provide insights for the discovery of novel therapeutic target of GC in the feature.
Research objectives
Cohorts data of GC patients was investigated from The Cancer Genome Atlas and Gene Expression Omnibus (GSE118916, GSE52138, GSE79973, GSE19826, and GSE84433).
Research methods
We performed a series of immune infiltration analyses using ESTIMATE, CIBERSORT, and ssGSEA. Furthermore, weighted gene co-expression network analysis was conducted to identify the immune-related genes.
Research results
CD93 significantly enriched in tumor tissues. Additionally, higher expression of CD93 was significantly associated with shorter overall survival, less proportion of CD8 T and activated nature killer cells in the TME, and lower tumor mutational burden.
Research conclusions
CD93 is a novel prognostic and diagnostic biomarker for GC, which is closely related to the immune infiltration in TME.
Research perspectives
CD93 can serve as a potential therapeutic target for the immunotherapy of GC in the feature.
